ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
Social Capital Suvretta Holdings Corporation III

Social Capital Suvretta Holdings Corporation III (DNAC)

9,28
0,00
(0,00%)
Fermé 21 Septembre 10:00PM
0,00
0,00
(0,00%)
Après les heures de négociation: -

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

Dernier
9,28
Prix Achat
9,30
Prix Vente
9,50
Volume échangé
-
0,00 Fourchette du Jour 0,00
0,00 Plage de 52 semaines 0,00
Cap du marché
Clôture Veille
9,28
Ouverture
-
Dernière Transaction
Dernière heure de transaction
Volume financier
-
VWAP
-
Volume moyen (3 m)
-
Actions en circulation
67 138 000
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-17,57
Bénéfice par action (BPA)
-0,53
Chiffre d'affairess
-
Bénéfice net
-35,47M

À propos de Social Capital Suvretta Holdings Corporation III

Social Capital Suvretta Holdings Corp III is a blank check company. Social Capital Suvretta Holdings Corp III is a blank check company.

Secteur
Biological Pds,ex Diagnstics
Industrie
Blank Checks
Siège social
Grand Cayman, Cym
Fondé
2022

DNAC Dernières nouvelles

Revolutionary Chronic Kidney Disease Therapeutics Company ProKidney to List on the Nasdaq Following Business Combination with Social Capital Suvretta Holdings Corp. III

ProKidney Class A ordinary shares to begin trading on Nasdaq under the ticker symbol “PROK” on July 12, 2022 ProKidney receives total gross proceeds of approximately $597 million, expected to...

Social Capital Suvretta Holdings Corp. III Announces Reconvened Extraordinary General Meeting of Shareholders

Social Capital Suvretta Holdings Corp. III (“SCS”) today announced that it will reconvene the Extraordinary General Meeting of its shareholders to vote on the Business Combination Agreement...

ProKidney Corroborates the Mechanism of Action of REACT™ with Cell Marker Analysis in Patients with Diabetic Chronic Kidney Disease

WINSTON-SALEM, N.C., June 23, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (CKD...

ProKidney Announces Manufacturing Efficiency Initiatives and Supply Chain Streamlining Expected to Reduce REACT™ Manufacturing Costs

WINSTON-SALEM, N.C., June 15, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (“ProKidney”), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease (“CKD”...

Observed Safety Profile Supports Bilateral Dosing of ProKidney’s REACT™ – 007 Update

Potential for Amplified Therapeutic Effect of REACT™ with Bilateral Kidney Injections Potential to report data from enhanced delivery approach 1Q 2023 WINSTON-SALEM, N.C., June 07, 2022 (GLOBE...

ProKidney to present at upcoming investor conferences

WINSTON-SALEM, N.C., May 20, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (CKD...

ProKidney highlights key registrational program elements supporting advancement of REACT®

WINSTON-SALEM, N.C., May 03, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (CKD...

ProKidney and Social Capital Suvretta Holdings Corp. III (“SCS”) to Host Analyst and Investor Day on April 28, 2022

WINSTON-SALEM, N.C., April 18, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney) is a leading Phase 3 clinical-stage cellular therapeutics company with Regenerative Medicine Advanced Therapy...

ProKidney confirms Phase 3 program for autologous kidney cell therapy REACT®

WINSTON-SALEM, N.C., April 12, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (“ProKidney”), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease...

ProKidney Announces Online Publication of Trial Design for Phase II Multicenter Clinical Trial of REACT® Autologous Cell Therapy for Treatment of Chronic Kidney Disease

Article published online in American Journal of Nephrology; to be included in future print edition WINSTON SALEM, N.C., Jan. 27, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (“ProKidney”), a leading...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
BNZIBanzai International Inc
US$ 5,645
(96,01%)
61,39M
ZJYLJin Medical International Ltd
US$ 3,975
(50,00%)
1,24M
ANEBAnebulo Pharmaceuticals Inc
US$ 2,9001
(39,43%)
78,85k
XPONExpion360 Inc
US$ 0,081
(39,18%)
1,46B
AENTAlliance Entertainment Holding Corporation
US$ 2,74
(34,31%)
4,23M
GSIWGarden Stage Ltd
US$ 1,34
(-82,89%)
26,44M
CRBPCorbus Pharmaceuticals Holdings Inc
US$ 19,51
(-62,26%)
12,29M
LGCBLinkage Global Inc
US$ 0,4183
(-57,70%)
2,16M
BFIBurgerFi International Inc
US$ 0,0855
(-42,27%)
15,05M
SKYESkye Bioscience Inc
US$ 3,17
(-42,26%)
5,14M
XPONExpion360 Inc
US$ 0,081
(39,18%)
1,46B
NVDANVIDIA Corporation
US$ 116,00
(-1,59%)
378,16M
AAPLApple Inc
US$ 228,20
(-0,29%)
320,24M
INTCIntel Corporation
US$ 21,84
(3,31%)
261,68M
VERBVerb Technology Company Inc
US$ 0,0742
(33,45%)
178,65M
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock